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Objective: Serotonin-releasing agents prescribed as weight- 
loss medications have been implicated as a cause of ac- 
quired aortic and mitral valve abnormalities. Sibutramine 
hydrochloride (MERIDIAB) is a serotonin and norepi- 
nephrine reuptake inhibitor with proven efficacy of 
weight reduction. The purpose of this study was to deter- 
mine the incidence of cardiac valve disease in sibutramine- 
treated patients. 
Research Methods and Procedures: Obese patients with 
type 2 diabetes mellitus enrolled in an ongoing double- 
blind, placebo-controlled, parallel-arm, 12-month study of 
sibutramine (followed by a 12-month open label extension) 
underwent transthoracic echocardiographic imaging and 
color Doppler interrogation for assessment of cardiac valve 
anatomy and function. 
Results: A total of 210 patients were evaluated. Of these, 
133 were receiving sibutramine (72 in the double-blind pe- 
riod), and 77 were receiving placebo. The mean 2 Standard 
Deviation age was 5429 years, and the mean duration of 
treatment was 229+117 days (approximately 7.6 months). 
The prevalence of left-sided cardiac valve dysfunction 
was low and similar for the two treatment groups (sibutra- 
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mine 31133, or 2.3%; placebo 2/77, or 2.6%). All five cases 
were cases of aortic insufficiency; four were mild, one was 
severe (in a placebo patient). All three sibutramine cases 
were patients over age 50; two had a history of system- 
ic hypertension. 
Conclusion: The prevalence of left-sided cardiac valve dys- 
function was not higher than background in obese patients 
treated with sibutramine for an average of 7.6 months. 
Key words: anti-obesity drugs, heart valves, echocardiog- 
raphy, mitral valve insufficiency, aortic valve insufficiency 
Introduction 
Serotonin-releasing agents prescribed as weight-loss 
medications recently have been implicated as a cause of 
acquired aortic and mitral valve abnormalities. The initial 
report identified valve abnormalities among patients receiv- 
ing combination therapy with fenfluramine and phentermine 
(1). Subsequently, echocardiographic evidence of valve 
dysfunction was found among 92 (31.6%) of 291 asymp- 
tomatic patients treated at five centers with either dexfen- 
fluramine or fenfluramine with or without phentennine (2). 
These findings prompted voluntary withdrawal of dexfen- 
fluramine and fenfluramine in the United States and subse- 
quently from the worldwide market. More recently, two 
larger studies have confirmed an excess prevalence of mitral 
and aortic valve pathology among patients exposed to fen- 
fluramine, either with or without phentermine (3,4). A 
large-scale surveillance study has recently suggested no in- 
crease in valvular heart disease among patients treated with 
dexfenfluramine alone (5). The mechanism of acquired left- 
sided valve abnormalities associated with fenfluramine and 
dexfenfluramine has not been determined, but both fenflu- 
ramine and dexfenfluramine are serotonin-releasing agents. 
The valvular abnormalities that have been seen are morpho- 
logically similar to those noted in patients with the carci- 
noid syndrome. 
Sibutramine (MERIDIA@; Knoll Pharmaceutical Co., 
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Mt. Olive, NJ), an arylbutylcycloalkylamine, is a serotonin 
and norepinephrine reuptake inhibitor with demonstrated 
efficacy in weight management, Sibutramine has been ap- 
proved recently for use in the United States as a weight- 
control medication. Although it has a mechanism of action 
distinct from that of the serotonin-releasing agents fenflur- 
amine and dexfenfluramine, it does act on the serotonin 
system. The effect of sibutramine on cardiac valvular 
anatomy and function has not been reported previously. 
Similarly, the effects of other reuptake inhibitors that act on 
serotonin (e.g., fluoxetine, venlafaxine, sertraline, imipra- 
mine, amitriptyline) on cardiac valvular anatomy and func- 
tion have not been reported. 
The incidence of significant left-sided valvular heart 
disease in a population of asymptomatic subjects is known 
to be low. However, robust data are currently available only 
in a general population of relatively young age (6). The 
incidence of valvular heart disease is known to be higher 
among patients who are older or who have systemic hyper- 
tension (7-1 0). The incidence of echocardiographically de- 
tectable valvular heart disease in a population of middle- 
aged obese patients, representative of patients in whom 
valve disease was observed in association with fenfluramine 
and dexfenfluramine therapy has only recently been de- 
scribed (43). 
The purpose of the present study was twofold. First, we 
sought to evaluate the incidence of significant echocardio- 
graphically detectable left-sided valvular heart disease in a 
group of obese patients referred for but not treated with 
weight-loss drugs. Second, we sought to evaluate the preva- 
lence of echocardiographically detectable left-sided valve 
abnormalities among patients treated with sibutramine. 
Methods 
Patients and Study Design 
Eligible patients, all of whom were currently enrolled 
in an ongoing multicenter study of sibutramine, were evalu- 
ated with transthoracic echocardiography and Doppler in- 
terrogation of all four cardiac valves. The ongoing study 
was a randomized, double-blind, placebo-controlled, paral- 
lel-arm, 12-month study followed by 12 months of open 
label therapy in obese patients with type 2 diabetes mellitus 
who had not received antidiabetic medication previously. 
All patients were between 25 and 70 years of age and had a 
body mass index (BMI, weightkeight2)228 kg/m2 (obesity 
threshold = 27 kg/m2) at the start of the ongoing study. Pa- 
tients were excluded from participation in the echocardiog- 
raphy study if they had known preexisting documented val- 
vular heart disease (except for non-clinically significant mi- 
tral valve prolapse) prior to initiation of the ongoing weight- 
loss study or if they had used centrally active prescription 
weight-control medications for more than 1 week within the 
previous 5 years. Patients in the double-blind phase were 
receiving either sibutramine 15 mg or placebo daily. Pa- 
tients in the open treatment phase were receiving sibutra- 
mine 15 mg daily, although the dose could be increased to 
20 mg if they gained weight on 15 mg. All patients provided 
written informed consent and the protocol was approved by 
the ethical committees at the participating centers. 
Echocardiography 
All patients in the above noted ongoing sibutramine 
study were contacted to undergo echocardiographic screen- 
ing while still enrolled in the study and while still on study 
medication (placebo or sibutramine). Each patient under- 
went transthoracic two-dimensional echocardiography and 
color Doppler examination with specific attention to the 
presence or absence of valvular abnormalities. Transthorac- 
ic echocardiography was performed using current genera- 
tion two-dimensional echocardiographic scanners. Instru- 
mentation provided two-dimensional images at 275"  sec- 
tor, at 230 Hz frame rate with 2 128 grey scale shades and 
color flow imaging at frame rates 2 14 Hz. Transducer fre- 
quency varied from 2 to 5 MHz depending on the available 
imaging windows. Standard echocardiographic views were 
recorded on videotape and transferred to a central laboratory 
for interpretation. 
Left ventricular internal short axis dimensions, wall 
thickness, and left atrial dimensions were all measured from 
the parasternal long axis view directly from the two- 
dimensional image. The left ventricular internal dimension 
was measured in diastole, as timed from the R-wave, and in 
systole, as the smallest internal dimension at the level of the 
mitral valve chordae. The left atrial dimension was mea- 
sured in systole. 
For both the aortic and mitral valves, an anatomic as- 
sessment was made of valvular morphology, which in- 
cluded categorization as either normal, showing mild de- 
grees of age-related fibrosis, showing a pathologic degree of 
either focal or diffuse thickening and fibrosis, or showing a 
distinct mass. Additionally, valves were categorized with 
respect to obvious identifiable pre-existing structural lesions 
such as typical rheumatic heart disease with mitral stenosis, 
bicuspid aortic valve, etc. 
Aortic insufficiency was categorized as absent, mini- 
mal (within normal limits), mild, moderate, or severe using 
a combination of qualitative and quantitative parameters. 
For aortic insufficiency, qualitative parameters included 
depth of penetration into the left ventricular outflow tract as 
well as overall jet area, density of the spectral profile signal, 
and presence of reversal of flow in the descending thoracic 
aorta. Quantitative parameters included pressure half time 
of aortic insufficiency jet deceleration and assessment of the 
aortic insufficiency jet height, indexed to left ventricular 
outflow tract dimension. For the latter, minimal aortic in- 
sufficiency was considered consistent with a jet height to 
outflow tract height ratio <5%, mild 5% to 20%, moderate 
21% to 59% and severe >60%. 
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Mitral insufficiency was evaluated qualitatively and 
quantitatively as absent, minimal, mild, moderate, or severe. 
Minimal mitral regurgitation was considered present when 
there was an incompletely developed jet that was not holo- 
systolic, was less than 2- to 3-mm in diameter at its origin 
and which penetrated less than 15 mm into the left atrium. 
Mild mitral insufficiency was considered present when 
there was a completely developed jet present throughout 
systole which encompassed <20% of the left atrial area. 
Mitral insufficiency was considered moderate for jets which 
encompassed 20% to 40% of the left atrial area and severe 
when >40% of the area was encompassed. 
Left-sided valve regurgitation was assumed to be of 
potential clinical significance based on the findings of pre- 
viously reported literature and at thresholds established for 
“case definition” by the United States Food and Drug Ad- 
ministration (2). In brief, mitral regurgitation was taken to 
be of potential clinical significance if greater than mild in 
severity, and aortic regurgitation if greater than minimal. 
Right-sided valvular lesions were evaluated on a quali- 
tative basis. Both the pulmonic and tricuspid valve were 
assessed for degrees of valvular thickening, prolapse, mass 
or other anatomic abnormalities. Pulmonic insufficiency 
was graded in a manner identical to that for aortic insuffi- 
ciency. Tricuspid insufficiency was graded in a manner 
identical to that for mitral insufficiency. Additionally, when 
tricuspid insufficiency was present, the spectral profile of 
the tricuspid regurgitation jet was used to estimate the right 
ventricular-right atrial pressure gradient. 
All echocardiograms were read by one of two ex- 
perienced echocardiographers (DSB or WFA) blinded to 
status or duration of drug therapy. A second independent 
blinded reading for aortic and mitral pathology was per- 
formed on 25% of studies. Any descrepancies were resolved 
by consensus. 
Statistical Analysis 
The treatment groups were classified as follows: 1) 
Patients randomized to sibutramine were included in the 
analysis as sibutramine patients; 2) Patients randomized to 
placebo who had echocardiography performed while receiv- 
ing placebo were classified as placebo patients; and 3) Pa- 
tients randomized to placebo who had echocardiography 
performed while receiving sibutramine in the open- 
treatment phase were classified as sibutramine patients. 
For ordinal categorical data, the Cochran-Mantel- 
Haenszel (CMH) procedure (1 1,12) was used to generate an 
overall comparison between the treatment groups. For bi- 
nary data, point estimates and 90% confidence intervals 
were computed for the treatment proportions, for the differ- 
ence in treatment proportions and for the odds ratio. All 
computations were performed using the FREQ procedure in 
SAS@ (version 6.12) (13). 




Sibutramine double-blind* Overall 
( ~ 1 3 3 )  (n=72) Placebo (n=77) (n=210) 
Male [n (%)I 52 (39.1) 35 (48.6) 34 (44.2) 
Female [n (%)I 81 (60.9) 37 (5 1.4) 43 (55.8) 
Age (mean 2 S years)? 54.0+9 53.2_+9 5 4 . 8 8  
(range 25-71) (range 25-68) (range 35-7 1) 
Age <50 years [n (%)I 36 (27.1) 21 (29.2) 24 (31.2) 
Age 2-50 years [n (%)I 97 (72.9) 51 (70.8) 53 (68.8) 
Duration of Treatment 229+ 134 227+82 228k79 
(mean + S days) (range 14-487) (range 79-375) (range 86-379) 
Duration of Treatment 56 (42.1) 25 (34.7) 23 (29.9) 
<180 days [n (%)I 
Duration of Treatment 77 (57.9) 47 (65.3) 54 (70.1) 
1 1  80 days [n (%)I 
History of Hypertension [n (%)I 58 (43.6) 29 (40.3) 37 (48.1) 
*Patients in the double-blind phase at the time of echocardiography; this group is a subset of the sibutramine group. 
tS, standard deviation. 
86 (41 .O) 
124 (59.0) 
54.3+9 
(range 25-7 1) 
60 (28.6) 
150 (7 1.4) 
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Results 
Study Patients 
Two hundred and thirty-seven patients were enrolled in 
the initial double-blind, placebo-controlled study of weight 
loss in diabetic patients. Of these, 25 (10.5%) discontinued 
participation prior to performance of echocardiography, 20 
due to adverse events (none of which were consistent with 
cardiac valve disease) and 5 for other reasons. Of the 212 
patients remaining, one was excluded from participation 
because of a history of aortic valve disease that predated 
entry into the weight-loss study, and another underwent 
echocardiography but was excluded from the analysis be- 
cause an abnormal echocardiogram indicating aortic and 
mitral valve disease that predated entry into the weight-loss 
study was discovered. All of the remaining 210 patients 
participated in the echocardiography study, and all (100%) 
underwent echocardiographic imaging and analysis. 
Of the 210 patients analyzed, 149 were in the double- 
blind treatment phase, with 72 receiving sibutramine and 77 
receiving placebo. The remaining 61 patients were in the 
open treatment phase at the time of echocardiography. Pa- 
tients in the study had received sibutramine or placebo for 
7.6k3.9 months (Table 1). Baseline characteristics were 
comparable for the treatment groups (Table 1). The majority 
of the patients were over the age of 50 (71%) and female 
(59%). Almost half (45%) of the patients had a history 
of hypertension. 
Echocardiographic Imaging 
There were no significant differences between treat- 
ment groups in any echocardiographic parameter. A total of 
54 (25.7%) of the 210 echocardiograms underwent both 
primary and secondary review. There was a single (1 of 54, 
or 1.9%) discrepancy between readers for analysis of left- 
sided cardiac valvular dysfunction, in which aortic regurgi- 
tation was graded as mild by one observer and minimal by 
the second. Agreement was therefore 53 of 54 (98.1%) 
echocardiograms and 107 of 108 (99.1 %) left-sided valves. 
The prevalence of echocardiographic valve thickening 
for all valves is shown in Table 2. There were no significant 
differences in the prevalence of valve thickening between 
treatment groups. The incidence of Doppler evidence of 
valve regurgitation is shown in Table 3. The rates of valve 
regurgitation were low and similar for both treatment 
groups. The prevalence, 90% confidence intervals and odds 
ratio for left-sided valve dysfunction are shown in Table 4. 
The 90% confidence interval for the difference between 
sibutramine and placebo was narrow and included zero well 
within the interval. Similar results were obtained when pa- 
Table 2. Echocardiographic valve thickening by treatment group [number (%)]. 
p-value 
n Normal? Thickened (focal) (diffuse) Evaluable Placebo 
Thickened$ Thickened$ Not vs. 
Aortic 
Sibutramine (all) 133 
Sibutramine (double-blind)* 72 
Placebo 77 
Sibutramine (all) 133 
Sibutramine (double-blind)” 72 
Placebo 77 
Sibutramine (all) 133 
Sibutramine (double-blind)” 72 
Placebo 77 
Sibutramine (all) 133 





























14 (10.5) 1 (0.8) 
9 (12.5) l(1.4) 
6 (7.8) l(1.3) 
18 (13.5) l(0.8) 
12 (16.7) 0 







*Patients in the double-blind treatment phase at the time of echocardiography; this group is a subset of the sibutramine group. 
+Includes normal and age-normal. 
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Table 3. Doppler evidence of valve regurgitation by treatment group [Number (%)I 
Severity of valvular regurgitation 
Valvular abnormality Not p-value vs. 
Treatment group n None Minimal Mild Moderate Severe evaluable Placebo 
Aortic insufficiency 
Sibutramine (all) 133 124(93.2) 6(4.5) 3 (2.3) 0 0 0 .64 
S ibu tramine (double-blind) * 72 
Placebo 77 
Sibutramine (all) 133 
Sibutramine (double-blind)* 72 
Placebo 77 
Sibutramine (all) 133 
S ibu tramine (double-blind) * 72 
Placebo 77 
Sibutramine (all) 133 






















































8 (6.0) .63 
3 (4.2) .80 
6 (7.8) 
8 (6.0) .7 1 
6 (8.3) .80 
6 (7.8) 
*Patients in the double-blind treatment phase at the time of echocardiography; this group is a subset of the sibutramine group. 
tients treated for less than 180 days were excluded from the 
analysis (Table 5 ) ,  and when only patients in the double- 
blind treatment phase of the study were included in the 
analysis (Table 6). 
Pertinent data for the five patients with echocardio- 
graphic evidence of left-sided cardiac valve dysfunction are 
summarized in Table 7. The mean duration of treatment for 
the three sibutramine-treated patients (7.2k6.2 months) was 
similar to that of the sibutramine group as a whole (7.6k4.5 
months). All three patients were over age 50 and two had a 
history of systemic hypertension. One patient had been re- 
ceiving sibutramine for only 3 weeks (following treatment 
with placebo for 1 year). The only hemodynamically sig- 
nificant lesion occurred in a placebo-treated patient found to 
have severe aortic insufficiency. 
Table 4. 90% confidence intervals (CI) and odds ratio 
for incidence of left-sided valve dysfunction* 
Incidence of 
valvular 
Treatment group disease 90% CI 
Sibutramine (n = 133) 2.3% (0.001,0.044) 
Placebo (n = 77) 2.6% (0.000,0.056) 
Odds ratio (sibutramine 
Sibutramine-Placebo -0.3% (-0.040,0.033) 
vs. placebo) 0.865 (0.189, 3.968) 
Table 5.90% confidence intervals (CI) and odds ratio 
for incidence of left-sided valve dysfunction*: Dura- 
tion of treatment 2 180 days 
Incidence of 
valvular 
Treatment group disease 90% CI 
Sibutramine (n = 77) 2.6% (0.000,0.056) 
Placebo (n = 54) 3.7% (0.000,0.079) 
Odds ratio (sibutramine 
Sibutramine-Placebo -1.1% (-0.063, 0.041) 
vs. placebo) 0.693 (0.131, 3.681) 
*Severity of mild or greater aortic insufficiency and/or moderate 
or greater mitral regurgitation. 
*Severity of mild or greater aortic insufficiency and/or moderate 
or greater mitral regurgitation. 
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Table 6.90% confidence intervals (CI) and odds ratio 
for  incidence of left-sided valve dysfunction*: 
Double-blind portion of Study 
Incidence of 
valvular 
Treatment group disease 90% CI 
Sibutramine (n = 72) 1.4% (0.000,0.037) 
Placebo (n = 77) 2.6% (0.000,0.056) 
Odds ratio (sibutramine 
Sibutramine-Placebo -1.2% (-0.050,0.025) 
vs. placebo) 0.528 (0.07 1, 3.93 1) 
*Severity of mild or greater aortic insufficiency and/or moderate 
or greater mitral regurgitation. 
Discussion 
Background Prevalence of Valve Disease 
Available literature has addressed the prevalence of 
valvular heart disease among a young, normal population 
and among older patients with and without systemic hyper- 
tension (6-12,14,15). The prevalence of significant valvular 
heart disease among middle-aged obese patients, represen- 
tative of those referred for weight loss therapy, has been 
noted recently to range from 1.3% (4) to 4.5% (5). In the 
study reported here, the prevalence of significant valvular 
regurgitation (FDA definition) was 2.6%. Although previ- 
ous reports have indicated a high prevalence of significant 
valvular heart disease among patients treated with fenflur- 
amine or dexfenfluramine (2), these were observational 
studies without placebo control. In this regard, the high 
observed prevalence of valvular heart disease could have 
been intrinsic to the population studied rather than a result 
of therapy with serotonin-releasing agents. 
In the present study, 77 patients referred for weight-loss 
therapy but treated with placebo underwent echocardio- 
graphic assessment. The demographics of the group re- 
flected a mean age of 55 years, body mass index of >28 
kg/m2 and a 48% incidence of systemic hypertension. 
Among this group, there was a low prevalence of significant 
left- or right-sided valvular heart disease. Based on these 
findings, obesity does not appear to be associated with an 
increased incidence of significant valvular heart disease. 
Therefore, the high observed incidence of cardiac valve 
dysfunction associated with fenfluramine or dexfenflur- 
amine therapy cannot be accounted for by the specific popu- 
lation studied. 
Sibutramine and Valvular Function 
Fenfluramine and dexfenfluramine are serotonin- 
releasing agents. Although sibutramine is a serotonin and 
norepinephrine reuptake inhibitor and therefore has a dif- 
ferent mechanism of action, it likewise acts on the serotonin 
system (16). The present study demonstrates that there is a 
low prevalence of significant valvular heart disease associ- 
ated with sibutramine therapy, which is equivalent to that 
observed among an appropriate control population. Our 
study suggests that serotonin-releasing agents and reuptake 
inhibitors may have disparate effects on heart valve mor- 
phology and function. Whether this is related to differential 
effects on extracellular serotonin levels is unknown. Neither 
the study reported here, nor previous studies of other 
weight-loss agents have evaluated actual blood seroto- 
nin levels. 
Study Limitations 
The average duration of therapy with sibutramine was 
7.6k4.5 months. Of note, cardiac valve dysfunction associ- 
ated with fenfluramine and dexfenfluramine therapy was 
clearly evident among patients treated for 6 months (2). 
More recent studies confirm the development of valvular 
heart disease in patients treated with fenfluramine for as 
little as 4 months and also suggest a higher prevalence in 
patients treated for longer periods (3). In the present study, 
selecting for only patients treated with sibutramine for 
2 180 days did not suggest any increase in the incidence of 
valvular heart disease, suggesting that duration of therapy 
was not a significant limitation. However, a very late effect 
of sibutramine on valvular anatomy or function cannot be 
excluded by the present study. 
The background prevalence of significant left-sided 
cardiac valve dysfunction among the placebo control group 
in the present study was 2.6%, which is slightly higher than 
that observed in the CARDIA study (6) of 4352 normal 
subjects. However, the CARDIA study included only sub- 
jects between 23 and 35 years of age. Available data suggest 
that the prevalence of valvular heart disease among a nor- 
mal population increases with age (7-10) and with a history 
of systemic hypertension (9). The greater age and a high 
prevalence of systemic hypertension likely account for the 
somewhat higher observed incidence of valvular heart dis- 
ease among the control population in the present study. 
Finally, approximately 7% of right-sided valves in this 
study could not be adequately imaged for accurate analysis 
of regurgitation. This is likely related to body habitus in the 
study’s population of obese patients. However, all left-sided 
valves could be adequately imaged in all patients. 
Conclusions 
In summary, the prevalence of left-sided valvular 
heart disease among patients treated with sibutramine 
was low and comparable to that observed among an appro- 
priate placebo control group. Thus, sibutramine does not 
appear to be a cause of valvular heart disease. As a seroto- 
nin and norepinephrine reuptake inhibitor, the lack of 
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Table 7. Patients with left-sided valve dysfunction* 
Treatment Duration of History of Valve 
Patient Age Sex group Study phase treatment hypertension abnormality 
A 59 M Sibutramine Open-label 3 weeks Yes Mild A1 
B 53 M Sibutramine Open-label 13 months No Mild A1 
C 64 F Sibutramine Double-blind 8 months Yes Mild A1 
D 61 F Placebo Double-blind 11 months Yes Mild A1 
E 47 M Placebo Double-blind 8 months No Severe A1 
*Severity of mild or greater aortic insufficiency and/or moderate or greater mitral regurgitation. 
AI, aortic insufficiency. 
valvular heart disease associated with sibutramine may 
be the reflection of a mechanism of action which is dis- 
tinct from that of the serotonin-releasing agents fenflur- 
amine and dexfenfluramine. 
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